Volume 19, Issue 2 (7-2025)
payavard 2025, 19(2): 105-114 |
Back to browse issues page
Ethics code: IR.SU.REC.1402.10
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Keramati K, Adib S, Ahmadi Hamedani M, Mohammadnejad Nasrabadi L. Hematological Evaluation of the Interaction of Broncho T.D® and Isoproterenol in Experimental Study. payavard 2025; 19 (2) :105-114
URL: http://payavard.tums.ac.ir/article-1-7784-en.html
URL: http://payavard.tums.ac.ir/article-1-7784-en.html
1- Associate Professor, Department of Basic Sciences, Faculty of Veterinary Medicine, Semnan University, Semnan, Iran , k.keramati@semnan.ac.ir
2- D.V.M. Candidate in Veterinary Medicine, Faculty of Veterinary Medicine, Semnan University, Semnan, Iran
3- Associate Professor, Department of Clinical Sciences, Faculty of Veterinary Medicine, Semnan University, Semnan, Iran
4- Ph.D. in Toxicology, Legal Medicine Research Center, Legal Medicine Organization, Tehran, Iran
2- D.V.M. Candidate in Veterinary Medicine, Faculty of Veterinary Medicine, Semnan University, Semnan, Iran
3- Associate Professor, Department of Clinical Sciences, Faculty of Veterinary Medicine, Semnan University, Semnan, Iran
4- Ph.D. in Toxicology, Legal Medicine Research Center, Legal Medicine Organization, Tehran, Iran
Abstract: (998 Views)
Background and Aim: BronchoT.D is an Iranian herbal drug manufactured for human consumption and has anti-cough and expectorant properties. Isoproterenol is a non selective agonist of beta-adrenergic receptors that although has been used as a drug in cases such as bradycardia, but based on the results of some studies, it has been determined that isoproterenol can also lead to tissue damage and hematological changes. The aim of this research was hematological evaluation of the interaction of BronchoT.D® with isoproterenol.
Materials and Methods: This was an experimental study. Eighteen male wistar rat were used in 3 experimental groups (each group 6 rats) including control, recipient of isoproterenol and normal saline and recipient of isoproterenol and BronchoT.D. There was no intervention in the control group. Isoproterenol was administered via twice injection and normal saline and BronchoT.D were administered five times orally. Finally, blood was collected from the rats and White Blood Cells (WBC), Red Blood Cells (RBC), Hematocrit (Hct), Hemoglobin (Hgb), Mean Corpuscular Volume (MCV), Mean Corpuscular Hemoglobin Concentration (MCHC) and Platelets (Plt) were measured. Statistical analysis of data was performed through one-way analysis of variance using SPSS software.
Results: In terms of WBC, the difference between the experimental groups was not significant. The isoproterenol and normal saline receiving group had a significant increase in terms of RBC, Hct, Hgb and Plt as compared to the control group. The difference between the isoproterenol and BronchoT.D receiving group was not significant in terms of RBC, Hct and Plt as compared to the control group. In terms of Hgb and MCHC, the isoproterenol and BronchoT.D receiving group had a significant increase as compared to the control group. In term of MCV, the difference between experimental groups was not significant. The isoproterenol and normal saline receiving group did not differ significantly in comparison with the control group in term of MCHC.
Conclusion: Based on the findings of this study, it can be concluded that BronchoT.D not only prevents some hematological changes caused by isoproterenol, such as an increasing of RBC and plt, but can also increase the oxygen-carrying capacity of blood through a significant increase in Hgb and MCHC. BronchoT.D probably causes such effects by counteracting oxidative stress or by directly affecting the bone marrow, although additional researches are necessary to investigate such probablities.
Materials and Methods: This was an experimental study. Eighteen male wistar rat were used in 3 experimental groups (each group 6 rats) including control, recipient of isoproterenol and normal saline and recipient of isoproterenol and BronchoT.D. There was no intervention in the control group. Isoproterenol was administered via twice injection and normal saline and BronchoT.D were administered five times orally. Finally, blood was collected from the rats and White Blood Cells (WBC), Red Blood Cells (RBC), Hematocrit (Hct), Hemoglobin (Hgb), Mean Corpuscular Volume (MCV), Mean Corpuscular Hemoglobin Concentration (MCHC) and Platelets (Plt) were measured. Statistical analysis of data was performed through one-way analysis of variance using SPSS software.
Results: In terms of WBC, the difference between the experimental groups was not significant. The isoproterenol and normal saline receiving group had a significant increase in terms of RBC, Hct, Hgb and Plt as compared to the control group. The difference between the isoproterenol and BronchoT.D receiving group was not significant in terms of RBC, Hct and Plt as compared to the control group. In terms of Hgb and MCHC, the isoproterenol and BronchoT.D receiving group had a significant increase as compared to the control group. In term of MCV, the difference between experimental groups was not significant. The isoproterenol and normal saline receiving group did not differ significantly in comparison with the control group in term of MCHC.
Conclusion: Based on the findings of this study, it can be concluded that BronchoT.D not only prevents some hematological changes caused by isoproterenol, such as an increasing of RBC and plt, but can also increase the oxygen-carrying capacity of blood through a significant increase in Hgb and MCHC. BronchoT.D probably causes such effects by counteracting oxidative stress or by directly affecting the bone marrow, although additional researches are necessary to investigate such probablities.
Type of Study: Original Research |
Subject:
Laboratory Sciences
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
